(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 7.35% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Neogenomics's revenue in 2025 is $709,162,000.On average, 16 Wall Street analysts forecast NEO's revenue for 2025 to be $94,647,176,432, with the lowest NEO revenue forecast at $90,788,832,206, and the highest NEO revenue forecast at $99,202,920,905. On average, 16 Wall Street analysts forecast NEO's revenue for 2026 to be $103,968,273,616, with the lowest NEO revenue forecast at $98,866,512,622, and the highest NEO revenue forecast at $109,650,985,835.
In 2027, NEO is forecast to generate $113,555,909,670 in revenue, with the lowest revenue forecast at $106,854,915,456 and the highest revenue forecast at $122,271,471,945.